AstraZeneca and Galderma Enter into R&D Collaboration to Develop New Treatments for Dermatological Diseases
AstraZeneca and Galderma Pharma S.A. announced they have entered into a R&D collaboration to develop new treatments for dermatological conditions including psoriasis, acne and atopic dermatitis which significantly affect the health and quality of life for millions of people worldwide.
Under the terms of the agreement, Galderma will have exclusive access to a number of compounds from across AstraZeneca’s portfolio to develop in dermatological indications. Initial targets for collaboration have already been identified from disease areas as diverse as oncology, inflammation and central nervous system. These will be interrogated based on translational science and pre-clinical testing to determine the ones that will progress in the collaboration. The financial terms of the five-year agreement were not disclosed.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Insect wings inspire new ways to fight superbugs - Scientists reveal how nanomaterials inspired by insect wings are able to destroy bacteria on contact
Why do BRCA1 mutations cause predominantly breast and ovarian cancer?
Mixing energy drinks, alcohol may affect adolescent brains like cocaine

Magnesium deprivation stops pathogen growth

Stress factor regulates obesity - Researchers find new link to cell's recycling system
Feldan Therapeutics and Elasmogen announce research agreement with Amgen - Agreement to develop intracellular biologics
United_States_Department_of_Health,_Education,_and_Welfare
CRISPR/Cas9 Silences Gene Associated with High Cholesterol
Ezetimibe reduces cardiovascular events in diabetics with recent acute coronary syndrome
Novartis discontinues development of two investigational compounds - Strategic focus remains on differentiated products and agents most likely to address unmet patient need
DIA appoints Kaushik Desai as DIA India Director
